GlassScriptPhysician profile
Sayed S Ahmed
NPI 1194160739
$1,755.88
in general payments reported to CMS, 2019-2025
17 companies · $318 in 2025
The $318 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.76 · 2020: $76.67 · 2021: $85.35 · 2022: $284 · 2023: $623 · 2024: $316 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.25 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $441.70 | 2022-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $251.60 | 2022-2025 | |
| Medtronic, INC. | $211.88 | 2023 | Ellipsys Vascular Access System |
| Otsuka America Pharmaceutical, INC. | $165.61 | 2021-2024 | Jynarque |
| Horizon Therapeutics Plc | $155.73 | 2020-2022 | |
| Vifor Pharma, INC. | $110.02 | 2022-2025 | Veltassa |
| Travere Therapeutics, INC. | $76.47 | 2023-2025 | |
| Glaxosmithkline, LLC. | $64.73 | 2023-2024 | Benlysta |
| Calliditas Therapeutics US INC. | $60.40 | 2022-2025 | Tarpeyo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.57 | 2019 | |
| Novartis Pharmaceuticals Corporation | $47.35 | 2024-2025 | |
| Amgen INC. | $32.85 | 2024-2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $28.50 | 2023 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $24.12 | 2023 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $13.31 | 2022 | |
| Akebia Therapeutics INC | $4.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayed Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.